Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia

British Journal of Clinical Pharmacology

Volumn 76, Issue 3, 2013, Pages 412-424

  Van Hasselt, J G Coen ^a   Gupta, Anubha ^b   Hussein, Ziad ^b   Beijnen, Jos H ^a,c   Schellens, Jan H M ^a,c   Huitema, Alwin D R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EISAI CO LTD   (Japan)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Eribulin mesilate; Haematological toxicity; Modelling; Neutropenia; NONMEM; Pharmacodynamics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ERIBULIN; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; PROTEIN;

ADULT; AFRICAN AMERICAN; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CAUCASIAN; CHEMOSENSITIVITY; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; DRUG TRANSPORT; ETHNICITY; FEMALE; HUMAN; JAPANESE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PACIFIC ISLANDER; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; SIMULATION; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ERIBULIN MESILATE; HAEMATOLOGICAL TOXICITY; MODELLING; NEUTROPENIA; NONMEM; PHARMACODYNAMICS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FURANS; HUMANS; KETONES; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; RISK;

EID: 84882684026     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12143     Document Type: Article

References (27)

1. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
2. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377: 914-923.
3. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-4721.
4. Friberg LE, Sandström M, Karlsson MO. Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest New Drugs 2010; 28: 744-753.
5. Soto E, Keizer RJ, Trocóniz IF, Huitema ADR, Beijnen JH, Schellens JHM, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Invest New Drugs 2011; 29: 984-995.
6. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi M-C, Milano G, Schellens JHM, Huitema ADR. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 2008; 83: 829-839.
7. Van Hasselt JGC, Schellens JHM, Mac Gillavry MR, Beijnen JH, Huitema ADR. Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab. Pharm Res 2012; 29: 3499-3511.
8. Van Hasselt JGC, Boekhout AH, Beijnen JH, Schellens JHM, Huitema ADR. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clin Pharmacol Ther 2011; 90: 126-132.
9. Zandvliet AS, Schellens JHM, Copalu W, Beijnen JH, Huitema ADR. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. J Pharmacokinet Pharmacodyn 2009; 36: 39-62.
10. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, 2011.
11. Keizer RJ, Van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 72-79.
12. Beal SL, Boeckman AJ, Sheiner LB. NONMEM user guides. 1988.
13. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: comparison across Anticancer Drugs. Clin Cancer Res 2006; 12: 5481-5490.
14. Summary of product characteristics HALAVEN. EMA. 2012.
15. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009; 15: 4207-4212.
16. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, Rosen LS. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 4213-4219.
17. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27: 2954-2961.
18. Spira AI, Iannotti NO, Savin MA, Neubauer M, Gabrail NY, Yanagihara RH, Zang EA, Cole PE, Shuster D, Das A. A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non-Small-Cell Lung Cancer. Clin Lung Cancer 2012; 13: 31-38.
19. Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema ADR, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JHM, Beijnen JH. Mass Balance Study of 14C-eribulin in Patients with Advanced Solid Tumours. Drug Metab Dispos 2012; 40: 313-321.
20. Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol 2012; 70: 823-832.
21. Devriese LA, Witteveen PEO, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema ADR, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. Br J Clin Pharmacol 2013; 75: 507-515.
22. Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JHM. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs 2013; 31: 381-389.
23. Lesimple T, Edeline J, Carrothers TJ, Cvitkovic F, Darpo B, Delord J-P, Léna H, Penel N, Edwards GJ, Law K, Wanders J, Kristensen A, Reyderman L. A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Invest New Drugs 2012. DOI: 0.1007/s10637-012-9893-8
24. De Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012; 23: 1241-1249.
25. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28: 3922-3928.
26. Mukohara T, Nagai S, Mukai H, Namiki M, Minami H. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest New Drugs 2012; 30: 1926-1933.
27. Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012; 23: 1441-1448.